Evidence map›Paper›PMID 30565075›Full record

ArticleMolecular biology reports2019

Design of a recombinant immunotoxin against the human granulocyte-colony stimulating factor receptor.

E Babavalian, M Zeinoddini, A R Saeedinia, R Mohammadi, N Xodadadi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

E BabavalianMalek Ashtar University of Technology, Tehran, Iran.
M ZeinoddiniMalek Ashtar University of Technology, Tehran, Iran. zeinoddini52@mut.ac.ir.
A R SaeediniaMalek Ashtar University of Technology, Tehran, Iran.
R MohammadiMalek Ashtar University of Technology, Tehran, Iran.
N XodadadiMalek Ashtar University of Technology, Tehran, Iran.
Malek Ashtar University of Technology · IR

Funding

Malek Ashtar University of Technology Immunotoxin
6 · The paper itself

Abstract

Immunotoxin is a new strategy for protein therapy of cancer. This engineered protein contains two parts, the immune part which is an antibody or cytokine, directed against the cancer cell receptor, and the toxin part consisting of a plant or bacterial toxin leading to apoptosis by protein synthesis inhibition. The knowledge of cell-surface receptor overexpression in cancer cells can help scientists to construct new anti-cancer agents. The granulocyte colony stimulating factor (G-CSF) receptor is expressed on the cell surface of some blood cancers such as acute myeloid leukemia (AML). Therefore, this receptor can be used as an immunotoxin for treatment of some cancers. The aim of this work was to design and produce DT-GCSF immunotoxin using truncated DT fused to G-CSF. For fusion protein construction, DT389 and G-CSF fragments, were amplified by PCR using specific primers. A flexible linker SerGly4SerMet (SG4SM) was used to fuse the PCR products by SOEing PCR procedure to achieve an appropriate fusion protein, and the fused fragment was subcloned into pET21b. The new construction (pET-DT

Indexed as

ApoptosisDiphtheria ToxinEscherichia coliGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHumansImmunotoxinsLeukemia, Myeloid, AcuteProtein EngineeringReceptors, Colony-Stimulating FactorReceptors, Granulocyte Colony-Stimulating FactorRecombinant Fusion ProteinsRecombinant ProteinsDiphtheria ToxinGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorImmunotoxinsReceptors, Colony-Stimulating FactorReceptors, Granulocyte Colony-Stimulating FactorRecombinant Fusion ProteinsRecombinant ProteinsDiphtheria toxinExpressionGranulocyte colony-stimulating factorImmunotoxinPurification

Identifiers

PMID30565075
OpenAlexW2904198922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.